How a cluster of unexplained pneumonia cases in a Brisbane nursing home became a global public health emergency.
September 26 – January 18, 2025
On a Thursday morning in late September, two elderly residents of a nursing home in Kelvin Grove, Brisbane are transferred to the Royal Brisbane and Women's Hospital. The patients are 79 and 86 years old. Both have pneumonia. The standard respiratory panel comes back negative: not influenza, not RSV, not SARS-CoV-2, not any bacterial agent the lab tests for.
The next day, three more residents develop influenza-like symptoms. One, a 76-year-old, is admitted on September 28. Two more, ages unknown, follow on September 29. The nursing home now has five patients in hospital, and no diagnosis.
Queensland Health activates a rapid response team. The nursing home is placed under strict isolation: no visitors, limited staff movement. Contact tracing begins for every employee and resident who has passed through the facility in the past two weeks.
Over the next three days, nine more patients are hospitalized, all aged over 75. Then, on September 30, a case that changes the calculus: a 51-year-old caregiver is admitted with what doctors describe as atypical pneumonia. She has no underlying conditions. She is young, previously healthy, and now struggling to breathe. The pathogen, whatever it is, does not discriminate by age alone.
The Australian government raises the alert level. Laboratories begin urgent testing to identify the pathogen. Epidemiologists analyze case links and potential sources. Hospitals and aged care providers across Brisbane receive alerts to monitor and report similar cases. RBWH begins preparing additional isolation beds.
Children's Health Queensland Hospital notifies Queensland Health of a family cluster. A four-year-old was admitted on September 26 with respiratory distress and dehydration. The following day, the child's mother developed severe symptoms and was transferred to Princess Alexandra Hospital. A 12-year-old sibling was admitted on September 30 with atypical pneumonia. A 15-year-old sibling was also hospitalized. The respiratory panel was negative for known viruses and bacteria in all cases.
A response team is deployed. One hundred contacts are identified, mostly schoolmates of the 12-year-old. The family reports no travel history.
Meanwhile, nine more nursing home patients and another caregiver are hospitalized. The simultaneous emergence of two distinct clusters — one in aged care, one in a family with children — raises a question that no one wants to ask out loud: are they connected?
Queensland's Chief Health Officer convenes an emergency meeting with Metro North HHS, Queensland Health, and the Communicable Diseases Network Australia. The Australian Health Protection Principal Committee is briefed. Australia's National IHR Focal Point directly notifies WHO's Western Pacific Regional Office in Manila.
On October 7, the news that everyone feared: the first two deaths. Both are nursing home patients, aged 82 and 84, with several comorbidities. The WHO issues its first official alert.
A third death is reported on October 10: a 78-year-old nursing home patient. The Australian Government issues its first Public Health Advisory. By October 13, the Queensland CHO announces 25 new suspected cases admitted to five Brisbane hospitals: St Andrew's War Memorial, St Vincent's Private, RBWH, North-West Private, and Children's Hospital. Two cases are in small children, aged 1 and 3. Both are severe. These cases appear unlinked to the existing clusters.
Then, on October 14, the geographic boundary breaks. A patient is hospitalized in Townsville, a coastal city 1,300 kilometers north of Brisbane. The patient has a history of travel from Brisbane. A contact tracing unit is activated to identify passengers on the flight manifest.
Seven of the previously suspected Brisbane cases test positive for influenza and are removed from the investigation. But thirteen new suspected cases are hospitalized on October 14 alone. The net keeps growing.
Twenty-one days after the first two patients were admitted. The Doherty Institute in Melbourne achieves what the world has been waiting for: genetic identification of the causative agent through meta-sequencing of clinical specimens. The genome is published on GenBank the following day.
It is a novel paramyxovirus. Family Paramyxoviridae, genus Spookyvirus. Approximately 85% nucleotide identity with known Spookyviruses, especially in the conserved polymerase regions. But this one is different: lower virulence, broader human tissue tropism, and critically, human-to-human transmissibility. The suspected reservoir is native fruit bats, Pteropus species, with a likely zoonotic spillover event somewhere in Southeast Queensland.
It will eventually be designated Spooky-like Virus 2024 (SPOK-24), causing a disease named Spooky-Associated Respiratory Syndrome 2024 (SPOKARS-24).
PCR primers are developed by the Doherty lab on October 22, giving clinicians the first reliable diagnostic tool. Three days later, the WHO publishes its first situation report. The same day, a Lancet paper describes the clinical features of the first 70 patients.
On October 29, the New England Journal of Medicine publishes a correspondence detailing the early transmission dynamics. The picture is sobering.
| Finding | SPOK-24 | COVID-19 (early) |
|---|---|---|
| R₀ | 1.3 – 2.3 | ~2.5 |
| Incubation period | 2 – 4 days | 4 – 7 days |
| Serial interval | 4 – 8 days | 5 – 6 days |
| Fever | 94% | 89% |
| Cough | 69% | 68% |
| Viral pneumonia (imaging) | 87% | ~75% |
| Neurologic complications | 5.7% | Rare |
| ICU admission | 19% | ~25% |
| Case fatality (hospitalized) | 8.6% | ~10–15% |
WHO Situation Reports: cumulative hospitalizations, Weeks 42–45
85 total hospitalizations. Cases in Brisbane, Townsville, Rockhampton, and now Sydney. Seven deaths, including two children. The epidemic has broken containment in Queensland.
An Australian citizen working in New York City is admitted to New York-Presbyterian/Columbia University Irving Medical Center. He had recently traveled to Brisbane to visit family, and developed fever, muscle aches, and a runny nose shortly after landing at JFK. He tested positive for SPOK-24 on October 28.
The CDC and the New York City Department of Health launch an urgent contact-tracing operation on the flight manifest. The patient had not interacted with anyone in New York City aside from airport personnel and a taxi driver. He is in isolation, stable, and recovering.
WHO Situation Report #3 confirms what epidemiologists feared: the virus is no longer contained to Australia. Confirmed importations in Tokyo, Auckland, Christchurch, Port Moresby, New York, Hong Kong, and Bangkok. All with travel history from Brisbane. The household transmission study in Brisbane involving 50 families has begun. Nosocomial transmission is confirmed in multiple hospitals.
The WHO announces it is convening an Emergency Committee to assess whether SPOK-24 constitutes a Public Health Emergency of International Concern.
The WHO Director-General speaks from Geneva. The Emergency Committee has reviewed the evidence: sustained human-to-human transmission, confirmed international spread to 20 countries, 408 total hospitalizations, 24 deaths, contact tracing collapsed in Brisbane. The word that changes everything: Public Health Emergency of International Concern.
The cascade is immediate. On November 11, the USA, Russia, France, Spain, Italy, Ireland, Argentina, China, Switzerland, Belgium, Portugal, New Zealand, Taiwan, and Mexico restrict travel to and from Australia for humanitarian reasons only. Domestic travel within Australia drops to less than 10%.
Reports begin arriving from across the Western Pacific. Vietnam flags an anomalous increase in hospitalizations in the capital. Several cases, none with travel history to Australia, are confirmed as SPOK-24. South Korea identifies three independent clusters in Seoul, again without travel links. Japan confirms a dozen hospitalizations. Singapore and Thailand report their own clusters.
In the United States, the CDC's Traveler Genomic Surveillance program detects SPOK-24 genetic material in wastewater samples collected from aircraft and through the swab program at major West Coast airports. Within days, the first US hospitalizations due to SPOK-24 are confirmed.
The United States removes the travel-history requirement for SPOK-24 testing. The WHO recommends testing all patients presenting with respiratory symptoms. But it is too late for orderly surveillance: widespread shortages in diagnostic supplies and laboratory capacity are reported globally. The overlap with seasonal respiratory viruses creates a fog of uncertainty — a surge in influenza-like illness makes it impossible to distinguish SPOK-24 from common infections on symptoms alone.
By Christmas, cases are being detected across multiple US states. France confirms hospitalizations in Paris and begins regular reporting. The UK confirms cases in Manchester, London, and Glasgow. But at the same time, a different signal emerges from the other side of the world.
A preprint from the University of Queensland provides the first rigorous severity estimates, based on 247 Brisbane-area households with confirmed infections, clinical admissions across six Queensland hospitals, and surveillance of repatriation flights.
The findings reshape the risk calculus. Approximately 20% of infections are asymptomatic. Among symptomatic individuals, the infection fatality ratio rises steeply with age:
| Age group | IFR (symptomatic) | IHR (symptomatic) |
|---|---|---|
| 0–17 years | 0.03% | 1.9% |
| 18–49 years | 0.06% | 0.5% |
| 50–64 years | 0.1% | 1.5% |
| 65+ years | 4.0% | 20.1% |
An infection fatality ratio of 4% in the elderly. A hospitalization rate of one in five. And pediatric fatalities confirmed in both household and hospital cohorts. The paper's conclusion is measured but unambiguous: SPOK-24 poses a serious and age-stratified threat, with severity concentrated in the oldest and youngest populations.
By mid Jan 2025, the global situation is mixed. In Australia, the country where it all began, the epidemic curve appears to be plateauing, new hospitalizations are leveling off and case counts are flattening. The situation in South Korea and Japan is rapidly evolving. Both countries are reporting large numbers of hospitalizations and deaths, although official confirmation remains problematic due to shortages in testing capacity. Cases are growing in the United States, France, and the United Kingdom, as surveillance is strengthening. Time will tell whether this is going to be a long-lasting global concern or whether it will fizzle out.
Data and scientific information are from the SMH collaboration. Publicly available data worldwide are collected and maintained through the SPOKARS-24 Surveillance Dashboard.
SPOKARS-24 Surveillance Dashboard →